Nanoparticles could help move drugs past the blood–brain barrier, which blocks most medicines from reaching brain tissue. A 2024 study in Molecular Pharmaceutics shows how machine learning and related statistical models might help researchers choose nanoparticle designs before running costly animal experiments. The result is a method for guiding formulation work. It is not a brain treatment, and the nanoparticles it tested have not been shown to help patients.
What the 2024 study set out to do
The study by Yousfan and colleagues, titled “A Comprehensive Study on Nanoparticle Drug Delivery to the Brain: Application of Machine Learning Techniques” (Molecular Pharmaceutics 21(1), 333–345, 2024), asked a narrow question: which drug, formulation, and particle properties go with better brain delivery? Rather than running a new large set of experiments, the authors pooled published nanoparticle work and modeled the relationships in that data.
As an Amazon Associate I earn from qualifying purchases.
The main outcome was brain targeting measured as the ratio of drug exposure in brain to exposure in plasma, written as AUCbrain/AUCplasma. AUC (area under the concentration-time curve) summarizes how much drug stays in a tissue over time. A higher ratio means more of the drug reached the brain relative to the bloodstream. This is a pharmacokinetic measure, not a clinical one. The study did not track symptoms or disease outcomes.
How the model was built
The authors drew on data from 237 published papers. Their design matrix had 403 rows and 24 columns, with each row representing a measured case and each column an input or outcome. Some analyses used a reduced dataset of 133 observations and 12 predictors after data cleaning. The inputs fell into three groups:
#1 Best Overall
- Drug characteristics: molecular weight, solubility, log P, and whether the drug is a P-glycoprotein substrate (a transporter that can pump drugs back out of the brain).
- Preparation choices: factors such as the drug-to-carrier ratio and the release rate.
- Nanoparticle properties: particle size and zeta potential (a measure of surface charge).
The authors compared several linear modeling approaches: ordinary linear models, generalized linear models, and linear mixed-effects models. The mixed-effects approach performed best among those discussed. Its advantage was structural. Many measurements in the source papers came from the same animal, so they are not independent, and a mixed-effects model accounts for that clustering. Calling the work “machine learning” is accurate in its goals, but the models themselves are statistical regressions rather than a deep-learning system.
| Model family | What it handles | Result reported in the paper |
|---|---|---|
| Ordinary linear model | Single-level linear relationships | Compared; no separate headline score stated in the summary of the study |
| Generalized linear model | Linear predictors with non-normal outcome distributions | Compared; no separate headline score stated in the summary of the study |
| Linear mixed-effects model | Repeated measurements clustered by animal subject | Best performer among the approaches discussed |
Which factors the model associated with brain targeting
The paper reports different sets of candidate predictors depending on the route of administration. These are associations within the assembled literature data, not formulation rules that have been proven causal.
Rank #2
- Used Book in Good Condition
Intravenous administration
The regression analysis for intravenous dosing highlighted zeta potential, drug-to-carrier ratio, and release rate as potential predictors of brain targeting.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Intranasal administration
For intranasal dosing, the authors found relationships involving molecular weight, solubility, log P, particle size, and zeta potential. Intranasal delivery is often discussed as a way to bypass part of the barrier, but this study does not establish the mechanism behind these links.
Mixed-effects findings
The mixed-effects analysis linked a higher release rate and higher molecular weight with lower brain targeting. It also suggested a slight positive relationship for P-glycoprotein-substrate status. Since the release rate and molecular weight pushed targeting in the unfavorable direction in this dataset, the findings point toward designs that release more slowly and use smaller drugs. That is a hypothesis to test, not a rule the paper establishes.
Checking the predictions in mice
To test the model, the researchers made two phenytoin-loaded PLGA nanoparticle formulations and gave them to healthy female mice by intranasal or intravenous administration. They measured phenytoin in brain and blood over time. Phenytoin is an anti-seizure drug; the study used it as a model compound, not as a treatment being proposed for a brain disease.
Rank #4
- This Is Your Brain Funny Brain On Drugs.
- Funny Quote Ideas Tee for any occasions such as Mother's Day, Father's Day, Thanksgiving, Easter, Xmas, New Year, Halloween, Christmas, St.Patrick's Day, July 4th, Birthday, Valentine, Anniversary Days.
- Lightweight, Classic fit, Double-needle sleeve and bottom hem
| Formulation | Added component to PLGA | Species | Routes | Reported finding |
|---|---|---|---|---|
| Phenytoin-loaded PLGA with phospholipids | Phospholipids | Mice (healthy, female) | Intranasal or intravenous, per study design | Differences in brain and blood exposure by route and formulation; exact per-formulation values not stated in the source summary |
| Phenytoin-loaded PLGA with chitosan | Chitosan | Mice (healthy, female) | Intranasal or intravenous, per study design | Differences in brain and blood exposure by route and formulation; exact per-formulation values not stated in the source summary |
The paper reports that exposure differed by route and by formulation. It does not support a general claim that one route is clinically better than the other, and the study was not designed to make that comparison for patients.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
What the study does not establish
- It is preclinical. The validation used animals, not people. No human brain-delivery outcome was measured.
- The source data are heterogeneous. The 237 papers used different methods, models, and reporting styles. The authors themselves note that the predictive models need improvement.
- The test was narrow. One model drug, one carrier family (PLGA), two additives, and one species were examined.
- Predictions do not transfer automatically. Other drugs, particle compositions, diseases, or species would need their own testing.
- No efficacy claim follows. Higher brain exposure is not the same as therapeutic benefit.
Newer work in 2025
Two 2025 papers show the field moving in related directions. They should be read as separate studies, not as confirmation of the 2024 model.
Best Value
- Ideal Gift - Premium vegan leather cover with patterns. This easy-to-carry and versatile journal book will be an excellent gift on Christmas, Birthday, etc to convey your best wishes.
- Exquisite Design - Unique appearance, soft texture, easy to carry around. This journal book is suitable for home, office, outdoor adventure, and travel, etc. A classic vegan leather cover ensures well protection. In addition, it comes with a strap to ensure that the paper and accessories will not be scattered.
- Perfect size - 7.8" * 5" (20 cm * 12.5 cm) and has 70 pages (140 pages), perfect for carrying and writing. It can be easily put into a backpack, or purse, and travel anytime, anywhere.
- Multifunctional - Designed for easier reading and notes taking. It would be the perfect handy choice for you during daily uses, journeys, and work. Card slot bags are also included to organize your cards, tickets, photos, etc. And also a page-size slot with zipping for storing cash, cell phone, and more.
- This journal is also very suitable for use as bullet journals, daily planners, logbooks, food planners, artist sketchbooks, drawing, sketching, paintings, etc.
A larger computational framework
“Lab-in-the-loop machine learning for brain-targeting delivery system design,” published in Cell Biomaterials in 2025, described a framework built on 17,600 features extracted from 9,500 publications. It reported particle size and zeta potential among the important determinants of brain targeting, and used Bayesian optimization to propose candidate delivery systems. The “lab-in-the-loop” label refers to repeated cycles of prediction and laboratory testing. The candidates it proposes are computational outputs that still need experimental confirmation.
Lipid nanoparticles for mRNA delivery to the central nervous system
A 2025 Nature Materials paper reported lipid nanoparticles engineered to cross the blood–brain barrier and deliver mRNA to the central nervous system. It is an example of carrier engineering. It uses a different carrier type from the PLGA polymer particles in the 2024 modeling study, so results should not be merged across the two.
How to use this if you work on brain-targeted formulations
- Define the endpoint as the brain-to-plasma exposure ratio (AUCbrain/AUCplasma) and record it for every formulation, not only the best one.
- Log drug properties (molecular weight, solubility, log P, transporter status) alongside preparation variables (drug-to-carrier ratio, release rate) and particle properties (size, zeta potential).
- If several measurements come from the same animal, analyze them with a model that accounts for that clustering, such as a linear mixed-effects model, rather than treating each measurement as independent.
- Treat the model’s ranked factors as hypotheses. Test them with a fixed set of formulations, both routes where relevant, and blood and brain sampling over time.
- Do not carry results from one drug, carrier, or species to another without repeating the experiment.
Taken together, the work demonstrates a useful way to prioritize formulation experiments. It does not yet show that any nanoparticle reliably delivers a drug to the brain of a patient, and no commercially available brain-targeting nanoparticle product is identified in these sources.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →Publication details and figures above reflect the sources as of October 2026.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
